Status:
COMPLETED
Aspirin Resistance in Coronary Artery Disease
Lead Sponsor:
Vanderbilt University
Collaborating Sponsors:
National Heart, Lung, and Blood Institute (NHLBI)
Conditions:
Coronary Artery Disease
Eligibility:
All Genders
40+ years
Phase:
EARLY_PHASE1
Brief Summary
The purpose of this study is to evaluate possible mechanisms of aspirin resistance at a molecular level in aspirin-treated patients with coronary artery disease. We hypothesize that certain patient ch...
Detailed Description
Aspirin is commonly used for its antithrombotic effects in patients at risk for cardiovascular events. Its primary mechanism of action is the irreversible acetylation of platelet cyclooxygenase-1, the...
Eligibility Criteria
Inclusion
- On aspirin 81-325mg daily at time of enrollment
- Documented stable coronary artery disease or \> 6 months after coronary artery bypass grafting or interventional cardiac procedure
- Written informed consent
Exclusion
- Pre-menopausal female
- Renal disease (creatinine \>= 2 mg/dl)
- Anemia (Hematocrit \< 30%)
- Thrombocytopenia (platelet count \< 135,000/ul)
- Use of NSAIDs or coxibs within the previous 2 weeks
- Concurrent use of other anti-platelet agents
- Uncontrolled hypertension (systolic BP \> 180 mmHg)
- Decompensated congestive heart failure
- Recent coronary syndrome (\< 6 months)
- History of significant GI bleeding
Key Trial Info
Start Date :
June 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2014
Estimated Enrollment :
92 Patients enrolled
Trial Details
Trial ID
NCT00753935
Start Date
June 1 2006
End Date
March 1 2014
Last Update
April 19 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Vanderbilt University
Nashville, Tennessee, United States, 37232